We scan new podcasts and send you the top 5 insights daily.
Warma says immuno-oncology therapies often shrink tumors, but cancers relapse after four to six months because T cells become exhausted. Mongoose's platform reprograms T cells to persist for years and keep cancer in remission. He says solving persistence is as important as finding novel targets for solid tumors.
Overcoming the suppressive tumor microenvironment in solid tumors is tempting to solve by boosting binder affinity or adding co-stimulatory domains to T-cell engagers. However, this creates a double-edged sword: excessive stimulation can overactivate infiltrating T cells and drive them into dysfunction or exhaustion, sabotaging therapeutic efficacy.
Dr. Patrick Baeuerle argues the biggest challenge for cell engagers and CAR-T therapies is not killing power but the tumor's ability to down-regulate or lose the target antigen. This heterogeneity is a fundamental escape mechanism that future multi-targeting strategies must address to prevent relapse.
Instead of focusing solely on T-cells, Create's platform first targets myeloid cells, which constitute up to 60% of some solid tumors. Programming these cells transforms the tumor microenvironment, enabling a 5-10x influx of CD8 T-cells. This overcomes a key barrier for T-cell therapies in solid tumors.
Despite exciting early efficacy data for in vivo CAR-T therapies, the modality's future hinges on the critical unanswered question of durability. How long the therapeutic effects last, for which there is little data, will ultimately determine its clinical viability and applications in cancer versus autoimmune diseases.
The efficacy of Siltacel stems from a powerful initial expansion that eliminates cancer upfront. The CAR-T cells are often undetectable beyond six months, indicating their curative potential comes from an overwhelming initial response rather than persistent, long-term immune policing of the disease.
Companies like VIR are making progress with masked T-cell engagers that limit systemic toxicity like cytokine release syndrome (CRS). This approach, which concentrates efficacy at the tumor site, could be the key to unlocking the broad potential of T-cell engagers beyond hematologic malignancies into the much larger solid tumor market.
Unlike CAR-T therapies that rely on a limited number of engineered cells, T-cell engagers activate the body's entire T-cell repertoire. This vast pool of effector cells makes exhaustion a negligible issue, as only a small fraction is engaged at any time, ensuring a sustained attack on cancer cells.
The company combines two types of immune cells. One delivers a rapid, powerful initial attack to clear many cancer cells but doesn't persist. The other cell type remains longer to "clean up" any remaining cancerous cells, creating a more comprehensive and durable response.
Next-generation CELMoDs (iberdomide, mezagdomide) show promise beyond direct tumor killing. Their ability to reduce or reverse T-cell exhaustion suggests they could be used to 'prime' a patient's immune system, potentially restoring function before or after treatment with a CAR-T or bispecific T-cell engager.
Warma says CAR-T can only target extracellular antigens, limiting it to less than 3% of cancer patients. Mongoose Bio's TCR T-cell approach, from Cassian Yi at MD Anderson, goes after novel intracellular targets expressed on solid tumors. He says this opens treatment to patients who currently lack CAR-T options.